AR069462A1 - Inhibidores de mapk/ erk quinasa - Google Patents
Inhibidores de mapk/ erk quinasaInfo
- Publication number
- AR069462A1 AR069462A1 ARP080104939A ARP080104939A AR069462A1 AR 069462 A1 AR069462 A1 AR 069462A1 AR P080104939 A ARP080104939 A AR P080104939A AR P080104939 A ARP080104939 A AR P080104939A AR 069462 A1 AR069462 A1 AR 069462A1
- Authority
- AR
- Argentina
- Prior art keywords
- 10alkyl
- alkyl
- heteroc3
- heteroc1
- substituted
- Prior art date
Links
- 102000043136 MAP kinase family Human genes 0.000 title 1
- 108091054455 MAP kinase family Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 23
- 229910052739 hydrogen Inorganic materials 0.000 abstract 15
- 239000001257 hydrogen Substances 0.000 abstract 15
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 12
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 abstract 11
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 11
- -1 hydroxy, amino Chemical group 0.000 abstract 11
- 125000003118 aryl group Chemical group 0.000 abstract 10
- 150000002431 hydrogen Chemical group 0.000 abstract 10
- 239000007795 chemical reaction product Substances 0.000 abstract 9
- 125000006843 cycloalkyl-C1-5-alkyl Chemical group 0.000 abstract 9
- 150000001875 compounds Chemical class 0.000 abstract 8
- 125000003282 alkyl amino group Chemical group 0.000 abstract 6
- 125000001475 halogen functional group Chemical group 0.000 abstract 6
- 125000004429 atom Chemical group 0.000 abstract 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000004104 aryloxy group Chemical group 0.000 abstract 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 3
- 125000001424 substituent group Chemical group 0.000 abstract 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000001727 in vivo Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 abstract 2
- 230000005723 MEK inhibition Effects 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000033 alkoxyamino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000000712 assembly Effects 0.000 abstract 1
- 238000000429 assembly Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005553 heteroaryloxy group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98727907P | 2007-11-12 | 2007-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR069462A1 true AR069462A1 (es) | 2010-01-27 |
Family
ID=40340592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080104939A AR069462A1 (es) | 2007-11-12 | 2008-11-12 | Inhibidores de mapk/ erk quinasa |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8022057B2 (OSRAM) |
| EP (1) | EP2227469B9 (OSRAM) |
| JP (1) | JP5453290B2 (OSRAM) |
| AR (1) | AR069462A1 (OSRAM) |
| CA (1) | CA2705452C (OSRAM) |
| CL (1) | CL2008003366A1 (OSRAM) |
| ES (1) | ES2456966T3 (OSRAM) |
| PE (1) | PE20090998A1 (OSRAM) |
| TW (1) | TW200934775A (OSRAM) |
| WO (1) | WO2009064675A1 (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| BRPI0717374A2 (pt) | 2006-10-23 | 2013-10-29 | Takeda Pharmaceutical | Inibidores de mapk/erk quinase |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| PE20100747A1 (es) * | 2008-04-21 | 2010-11-03 | Novartis Ag | Compuestos heterociclicos como inhibidores de mek |
| AU2009296246B2 (en) | 2008-09-26 | 2015-07-30 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| EP2421612A1 (en) * | 2009-04-21 | 2012-02-29 | Novartis AG | Heterocyclic compounds as mek inhibitors |
| NZ599565A (en) * | 2009-11-04 | 2013-05-31 | Novartis Ag | Heterocyclic sulfonamide derivatives useful as mek inhibitors |
| WO2011067348A2 (en) | 2009-12-03 | 2011-06-09 | Novartis Ag | Mek inhibitor salts and solvates thereof |
| CN101747300B (zh) * | 2009-12-22 | 2012-11-07 | 上海大学 | 基于紫杉醇和氮芥的协同前药及其制备方法 |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| CN102020651B (zh) * | 2010-11-02 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 6-芳基氨基吡啶酮甲酰胺mek抑制剂 |
| UY34216A (es) * | 2011-07-27 | 2013-02-28 | Glaxo Group Ltd | Nuevos compuestos que inhiben la actividad de la Lp-PLA2 |
| AU2012290121B2 (en) | 2011-08-01 | 2015-11-26 | Genentech, Inc. | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors |
| WO2013086260A2 (en) * | 2011-12-09 | 2013-06-13 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| EP4306171A3 (en) | 2012-10-19 | 2024-04-03 | Array Biopharma, Inc. | Formulation comprising a mek inhibitor |
| CN105073195A (zh) | 2013-02-04 | 2015-11-18 | 昂科梅德制药有限公司 | 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测 |
| JP2015003902A (ja) | 2013-05-20 | 2015-01-08 | 杏林製薬株式会社 | 血管新生阻害剤 |
| WO2014204263A1 (en) | 2013-06-20 | 2014-12-24 | The Asan Foundation | Substituted pyridinone compounds as mek inhibitors |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| EP3046557A1 (en) | 2013-09-20 | 2016-07-27 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| US20170027940A1 (en) | 2014-04-10 | 2017-02-02 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
| AR101210A1 (es) | 2014-07-15 | 2016-11-30 | Genentech Inc | Métodos de tratamiento de cáncer usando antagonistas de unión al eje pd-1 e inhibidores de mek |
| WO2017058007A1 (en) | 2015-10-01 | 2017-04-06 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
| WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
| WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
| WO2018218633A1 (en) | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| MX2021001749A (es) | 2018-08-13 | 2021-05-27 | Beijing Percans Oncology Co Ltd | Biomarcadores para terapia contra el cancer. |
| CN111662282B (zh) * | 2019-03-07 | 2021-07-06 | 湖南化工研究院有限公司 | 氮杂环并吡啶类化合物及其中间体 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU616916B2 (en) * | 1987-11-20 | 1991-11-14 | Kissei Pharmaceutical Co. Ltd. | 4h-quinolizin-4-one compounds exhibiting therapeutic activities |
| JPH0670044B2 (ja) * | 1987-11-20 | 1994-09-07 | キッセイ薬品工業株式会社 | ４ｈ―キノリジン―４―オン誘導体 |
| AU5610398A (en) | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| AU2483400A (en) | 1999-01-13 | 2000-08-01 | Warner-Lambert Company | 4'heteroaryl diarylamines |
| PL401638A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
| JP2005526076A (ja) | 2002-03-13 | 2005-09-02 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋ阻害剤としてのｎ３アルキル化ベンズイミダゾール誘導体 |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) * | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| ES2331246T3 (es) * | 2003-07-24 | 2009-12-28 | Warner-Lambert Company Llc | Derivados de benzamidazol como inhibidores del mek. |
| US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| ATE495155T1 (de) * | 2003-11-19 | 2011-01-15 | Array Biopharma Inc | Heterocyclische inhibitoren von mek |
| US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| RU2364596C2 (ru) | 2004-06-11 | 2009-08-20 | Джапан Тобакко Инк. | ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ |
| US20070293544A1 (en) | 2004-11-24 | 2007-12-20 | Ulrich Abel | Novel 4-Arylamino Pyridone Derivatives as Mek Inhibitors for the Treatment of Hyper-Proliferative Disorders |
| AU2005311451A1 (en) | 2004-12-01 | 2006-06-08 | Merck Serono Sa | [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
| TW201238952A (en) * | 2005-05-18 | 2012-10-01 | Array Biopharma Inc | Heterocyclic inhibitors of MEK and methods of use thereof |
| BRPI0717374A2 (pt) | 2006-10-23 | 2013-10-29 | Takeda Pharmaceutical | Inibidores de mapk/erk quinase |
| CA2667961A1 (en) * | 2006-10-31 | 2008-05-08 | Takeda Pharmaceutical Company Limited | Mapk/erk kinase inhibitors |
| JO2985B1 (ar) * | 2006-12-20 | 2016-09-05 | Takeda Pharmaceuticals Co | مثبطات كينازmapk/erk |
| PE20100747A1 (es) * | 2008-04-21 | 2010-11-03 | Novartis Ag | Compuestos heterociclicos como inhibidores de mek |
| EP2421612A1 (en) | 2009-04-21 | 2012-02-29 | Novartis AG | Heterocyclic compounds as mek inhibitors |
-
2008
- 2008-11-07 WO PCT/US2008/082846 patent/WO2009064675A1/en not_active Ceased
- 2008-11-07 EP EP08849376.2A patent/EP2227469B9/en active Active
- 2008-11-07 JP JP2010533285A patent/JP5453290B2/ja active Active
- 2008-11-07 US US12/267,353 patent/US8022057B2/en active Active
- 2008-11-07 CA CA2705452A patent/CA2705452C/en not_active Expired - Fee Related
- 2008-11-07 ES ES08849376.2T patent/ES2456966T3/es active Active
- 2008-11-11 TW TW097143569A patent/TW200934775A/zh unknown
- 2008-11-12 CL CL2008003366A patent/CL2008003366A1/es unknown
- 2008-11-12 PE PE2008001910A patent/PE20090998A1/es not_active Application Discontinuation
- 2008-11-12 AR ARP080104939A patent/AR069462A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2456966T3 (es) | 2014-04-24 |
| EP2227469B1 (en) | 2014-01-08 |
| CA2705452C (en) | 2016-05-31 |
| JP2011503099A (ja) | 2011-01-27 |
| WO2009064675A1 (en) | 2009-05-22 |
| EP2227469B9 (en) | 2014-09-10 |
| US8022057B2 (en) | 2011-09-20 |
| PE20090998A1 (es) | 2009-08-12 |
| JP5453290B2 (ja) | 2014-03-26 |
| US20090124595A1 (en) | 2009-05-14 |
| CA2705452A1 (en) | 2009-05-22 |
| TW200934775A (en) | 2009-08-16 |
| CL2008003366A1 (es) | 2009-05-29 |
| EP2227469A1 (en) | 2010-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR069462A1 (es) | Inhibidores de mapk/ erk quinasa | |
| AR064640A1 (es) | DERIVADOS DE PIRIDO[2, 3-D]PIRIMIDIN-4, 7(3H, 8H)-DIONA, METODOS PARA SU PREPARACION E INTERMEDIARIOS DE SINTESIS, COMPOSICIONES FARMACEUTICAS, KIT DE ELEMENTOS Y ARTíCULO MANUFACTURADO QUE LOS COMPRENDEN Y SU USO EN LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR M | |
| ES2905318T3 (es) | Profármacos de riluzol y su uso | |
| ES2564250T3 (es) | Nuevo proceso para estatinas y sus sales farmacéuticamente aceptables de las mismas | |
| AR063232A1 (es) | Pirido (2,3) indoles como inhibidores de quinasas.composiciones farmaceuticas. | |
| JP2022541404A (ja) | インフルエンザウイルス感染症の治療に有用な化合物 | |
| AR063351A1 (es) | DERIVADOS DE PURINA Y DE PIRIMIDINAS CONDENSADAS, COMPOSICION Y SU USO EN LA PREPARACIoN DE UN MEDICAMENTO PARA INHIBIR EL HSP90 EN UNA CELULA. | |
| WO2016014522A1 (en) | Inhibitors of deubiquitinating proteases | |
| JP2008546731A5 (OSRAM) | ||
| AR077695A1 (es) | Derivados de pirimidina como inhibidores del factor ixa | |
| JP2009534358A5 (OSRAM) | ||
| FR2943669A1 (fr) | Derives de nicotinamide,leur preparation et leur application en therapeutique | |
| AR074863A1 (es) | Proceso y compuestos intermedios para preparar un inhibidor de proteasa macrociclico del vhc | |
| AR063357A1 (es) | Derivados de pirimidinas como inhibidores de mapk/erk quinasa. procesos de obtencion y composiciones farmaceuticas. | |
| WO2015178265A1 (ja) | 新規なグルタミン酸誘導体およびその用途 | |
| JP6176259B2 (ja) | 立体選択的なエポキシケトン化合物の製造方法 | |
| ES2756000T3 (es) | Nuevo procedimiento | |
| AR084864A1 (es) | Proceso de preparacion de girasa e inhibidores de topoisomerasa iv y compuestos intermediarios de dicho proceso | |
| AR070291A1 (es) | AZAINDOL-3-CARBOXAMIDAS CíCLICAS, SU PREPARACIoN, SU USO COMO PRODUCTOS FARMACÉUTICOS Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODULACIoN DE RAS. | |
| WO2010139967A8 (en) | Dihydroindole and tetrahydroisoquinoline derivatives useful as potassium channel inhibitors | |
| WO2010082212A3 (en) | N-biphenylacyl thiazolidine-2,4-dione derivatives, their synthesis and uses | |
| ES2371171B1 (es) | Derivados de camptotecina como agentes antitumorales. | |
| KR101564425B1 (ko) | 신규한 바이사이클릭 니트로이미다졸 카바메이트 화합물, 이를 제조하는 방법 및 이를 유효성분으로 함유하는 결핵 질환의 예방 또는 치료용 약제학적 조성물 | |
| WO2013124748A4 (en) | Novel polymorphs of azilsartan medoxomil potassium | |
| WO2012007619A1 (es) | Proceso de obtención de derivados solubles en agua de 20(s)camptotecina como agentes antitumorales |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |